Dexcom will stop producing G6 CGM sensors July 1, 2026, urging patients to switch to the smaller, more accurate G7 model.

DexCom, Inc. (NASDAQ:DXCM) is one of the best growth stocks to buy and hold forever. On September 22, UBS reiterated a ‘Buy’ rating on the stock and a $106 price target. The research firm reiterated ...

DexCom has a well-established record of introducing the most precise sensors for use in its continuous glucose monitors. On the strength of its technology, DexCom has captured an impressive slice of ...

However, Oppenheimer downgraded DexCom from Outperform to Perform, pointing to ongoing accuracy and performance challenges with the G7 device. Adding to the concerns, Hunterbrook Media released a ...

In other recent news, DexCom has been the focus of various analyst reports and market reactions regarding its G7 continuous glucose monitoring device. UBS maintained its Buy rating for DexCom, setting ...